$AMIX
Autonomix Medical, Inc.

2024 Q4 Form 10-Q Financial Statement

#000143774924034230 Filed on November 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.662M $1.352M
YoY Change 22.95% 107.89%
% of Gross Profit
Research & Development $1.174M $782.6K
YoY Change 50.02% 466.29%
% of Gross Profit
Depreciation & Amortization $45.00K
YoY Change
% of Gross Profit
Operating Expenses $2.836M $6.690M
YoY Change -57.61% 748.57%
Operating Profit -$2.836M -$5.820M
YoY Change -51.27%
Interest Expense $29.00K $24.55K
YoY Change 18.13%
% of Operating Profit
Other Income/Expense, Net $29.00K -$239.5K
YoY Change -112.11%
Pretax Income -$2.807M -$6.905M
YoY Change -59.35% 775.83%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.807M -$6.040M
YoY Change -53.53% 1248.21%
Net Earnings / Revenue
Basic Earnings Per Share -$2.47 -$8.78
Diluted Earnings Per Share -$2.47 -$0.33
COMMON SHARES
Basic Shares Outstanding 1.152M 23.04M 687.8K
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.155M $2.145M
YoY Change 140.29%
Cash & Equivalents $5.200M $2.145M
Short-Term Investments
Other Short-Term Assets $199.0K $62.30K
YoY Change 219.42%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.354M $2.208M
YoY Change 142.51%
LONG-TERM ASSETS
Property, Plant & Equipment $17.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $162.7K
YoY Change
Total Long-Term Assets $17.00K $162.6K
YoY Change -89.54%
TOTAL ASSETS
Total Short-Term Assets $5.354M $2.208M
Total Long-Term Assets $17.00K $162.6K
Total Assets $5.371M $2.370M
YoY Change 126.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $574.0K $402.9K
YoY Change 42.47%
Accrued Expenses $683.0K $34.60K
YoY Change 1873.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.257M $437.5K
YoY Change 187.31%
LONG-TERM LIABILITIES
Long-Term Debt $1.086M $61.70K
YoY Change 1660.13%
Other Long-Term Liabilities $4.795M
YoY Change
Total Long-Term Liabilities $1.086M $4.857M
YoY Change -77.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.257M $437.5K
Total Long-Term Liabilities $1.086M $4.857M
Total Liabilities $2.343M $5.295M
YoY Change -55.75%
SHAREHOLDERS EQUITY
Retained Earnings -$44.50M
YoY Change
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.028M -$2.924M
YoY Change
Total Liabilities & Shareholders Equity $5.371M $2.370M
YoY Change 126.6%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$2.807M -$6.040M
YoY Change -53.53% 1248.21%
Depreciation, Depletion And Amortization $45.00K
YoY Change
Cash From Operating Activities -$1.596M -$1.804M
YoY Change -11.54% 169.46%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 3.085M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.596M -1.804M
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000 3.085M
Net Change In Cash -1.596M 1.281M
YoY Change -224.62% -291.26%
FREE CASH FLOW
Cash From Operating Activities -$1.596M -$1.804M
Capital Expenditures $0.00
Free Cash Flow -$1.596M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001617867
dei Entity Registrant Name
EntityRegistrantName
Autonomix Medical, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1152120
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1152120
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
942575
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
942575
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q3 us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
CY2024Q3 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2024Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 pure
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
us-gaap Interest Expense Debt
InterestExpenseDebt
100000 usd
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
0 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41940
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1607810
dei Entity Address Address Line1
EntityAddressAddressLine1
21 Waterway Avenue, Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
The Woodlands
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77380
dei City Area Code
CityAreaCode
713
dei Local Phone Number
LocalPhoneNumber
588-6150
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
AMIX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1152149
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5155000 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8608000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
199000 usd
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
783000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
5354000 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
9391000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17000 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16000 usd
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
17000 usd
CY2024Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
16000 usd
CY2024Q3 us-gaap Assets
Assets
5371000 usd
CY2024Q1 us-gaap Assets
Assets
9407000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
574000 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
492000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
683000 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
285000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1257000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
777000 usd
CY2024Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1086000 usd
CY2024Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1002000 usd
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1086000 usd
CY2024Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1002000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
2343000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
1779000 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47502000 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
46596000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44475000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38969000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3028000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
7628000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5371000 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9407000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1662000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
793000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3461000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1295000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1174000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
471000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2128000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
839000 usd
CY2024Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-0 usd
CY2023Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-4556000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-0 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-4556000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2836000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5820000 usd
us-gaap Operating Expenses
OperatingExpenses
5589000 usd
us-gaap Operating Expenses
OperatingExpenses
6690000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2836000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5820000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5589000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6690000 usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-0 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
239000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
239000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
43000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
-0 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
84000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
-0 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
72000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
19000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
167000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
24000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
29000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-220000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
83000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-215000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2807000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6040000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5506000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6905000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2807000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6040000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5506000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6905000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.47
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.36
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1137468
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
687840
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1041950
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
666547
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
644000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-865000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2840000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2619000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6040000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
151000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
346000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2924000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
7628000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2699000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
360000 usd
CY2024Q2 amix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
0 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
5289000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2807000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
445000 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
101000 usd
CY2024Q3 amix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
0 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3028000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5506000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6905000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
805000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
151000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
88000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
101000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-0 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-4556000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
240000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-585000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
63000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
81000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
230000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
398000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-14000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3448000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1805000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2840000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
350000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
-0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
105000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3085000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3453000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1280000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8608000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
865000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5155000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2145000 usd
us-gaap Stock Issued1
StockIssued1
39000 usd
us-gaap Stock Issued1
StockIssued1
0 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
0 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
346000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5500000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6900000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3400000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1800000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44500000 usd
CY2024Q3 amix Working Capital Deficit
WorkingCapitalDeficit
4100000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5200000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Use of Estimates in Financial Statement Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but <em style="font: inherit;">not</em> yet billed by contract manufacturers, engineers and research organizations, warrant liability and the valuation of equity related instruments. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
amix Payments For Initial Public Offering Issuance Costs
PaymentsForInitialPublicOfferingIssuanceCosts
0 usd
amix Payments For Initial Public Offering Issuance Costs
PaymentsForInitialPublicOfferingIssuanceCosts
100000 usd
CY2024Q3 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
1100000 usd
CY2024Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
362267
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
510927
CY2024Q3 us-gaap Share Price
SharePrice
100
us-gaap Advertising Expense
AdvertisingExpense
100000 usd
us-gaap Advertising Expense
AdvertisingExpense
100000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
793000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
471000 usd
CY2023Q3 amix General And Administrative And Research And Development Expense
GeneralAndAdministrativeAndResearchAndDevelopmentExpense
1264000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1295000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
839000 usd
amix General And Administrative And Research And Development Expense
GeneralAndAdministrativeAndResearchAndDevelopmentExpense
2134000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-4600000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
200000 usd
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.02
CY2024Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
100000 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
729
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
76
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
100180
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
46.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
116303
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
27.69
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
-0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
-0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
216483
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
36.43
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
26463
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
40
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5000000 usd

Files In Submission

Name View Source Status
0001437749-24-034230-index-headers.html Edgar Link pending
0001437749-24-034230-index.html Edgar Link pending
0001437749-24-034230.txt Edgar Link pending
0001437749-24-034230-xbrl.zip Edgar Link pending
amix-20240930.xsd Edgar Link pending
amix20240930_10q.htm Edgar Link pending
ex_715370.htm Edgar Link pending
ex_715371.htm Edgar Link pending
ex_715372.htm Edgar Link pending
ex_715373.htm Edgar Link pending
ex_745156.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
logo.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
amix-20240930_def.xml Edgar Link unprocessable
amix-20240930_cal.xml Edgar Link unprocessable
amix-20240930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
amix20240930_10q_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
amix-20240930_pre.xml Edgar Link unprocessable